Impact of Copay Accumulator Programs on Health Insurance Costs

Larry Gruber, a fitness coach from Wilton Manors, Florida, has faced unexpected challenges with his health insurance. For years, he relied on a manufacturer coupon to help cover the high costs of Enbrel, a psoriatic arthritis medication priced above $7,700 per month. This coupon previously counted towards his deductible and out-of-pocket maximums, allowing Gruber to reach his insurance limits by February. However, his new insurer, Oscar Health, excluded the coupon from cost-sharing calculations, leaving Gruber to pay out-of-pocket until he meets his plan's $10,600 maximum.

This change stems from copay accumulator programs, a method increasingly used by health insurance carriers. Such programs prevent manufacturer coupons from counting towards deductibles and out-of-pocket expenses. According to Avalere Health, these programs have gained popularity over the past decade as insurers aim to manage the utilization of costly specialty drugs and control premium costs.

Despite their intended benefits, copay accumulator programs are criticized by patient advocacy groups for making medications less affordable and adding complexity for those on high-cost prescriptions. Insurers, including Oscar Health, argue these strategies are necessary for effective risk management in an environment of escalating healthcare costs.

Copay accumulator programs are not universally applicable. Federal regulations, including Medicare, Medicaid, and IRS guidelines on high-deductible health plans, prohibit these programs. However, individual and commercial group plans can implement them unless state regulatory compliance requirements dictate otherwise.

The adoption of copay accumulators varies across states. By 2026, nearly 40% of Affordable Care Act marketplace plans are expected to include such programs. Currently, 26 states, along with Washington, D.C., and Puerto Rico, have enacted laws to limit or ban them, while federal regulatory efforts remain static.

Advocates for patient affordability continue to push for federal intervention, following individual state measures since 2019. Proposed federal legislation, such as the HELP Copays Act, aims to mandate that financial assistance counts toward out-of-pocket costs, but progress is slow. This legislation targets federal health plans, including many employer-sponsored options.

Amid these regulatory complexities, industry experts advise careful research of insurance options, especially for those dependent on specialty medications. This could involve reviewing plan benefits or consulting state insurance regulators before committing to a policy. For Gruber, these changes mean shifting financial priorities, as funds once earmarked for savings may now be allocated to rising healthcare expenses. Both insurers and patient advocacy groups continue to seek mutually beneficial solutions across the healthcare landscape.